Home Sitemap Contact us Accessibility Statement Top of the page

Respiratory in focus

Our range of respiratory medicines means we share a common interest with respiratory specialists.

We focus on supporting the NHS and the Department of Health in managing long-term conditions like asthma and chronic obstructive pulmonary disease (COPD). We address cost-efficient prescribing and develop joined-up care through our Joint Working projects to help improve patient outcomes and also offer value for money. 

By recognising aligned goals and objectives in areas of mutual interest, we can work jointly to improve patient outcomes and enhance patient experience. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies.

Asthma and Chronic Obstructive Pulmonary Disease

Over five million people in the UK are currently receiving treatment for asthma and the NHS is thought to spend over £1 billion each year treating the condition.1

Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases in the UK – with over three million people living with the condition. However, only about 900,000 have formally been diagnosed,2 because people are reluctant to seek medical help, and often ignore their symptoms.

As well as developing and providing our own specialty medicines dedicated to the treatment of asthma and COPD, we provide a range of information, consultation and education services to help you manage and improve the service you provide to your patients. This includes inhaler technique training and helping patients understand how compliance and self management of their condition can benefit their overall health.

DuoResp Spiromax® (budesonide formoterol)

Aerivio Spiromax® (salmeterol xinafoate/fluticasone propionate)

Qvar® (CFC free beclometasone dipropionate)

Support for healthcare professionals

Support for healthcare professionals
  • For factual, scientific-based information about DuoResp Spiromax®, Aerivio Spiromax® or Qvar® Easi-Breathe® you can contact our Medical Information Service via email medinfo@tevauk.com or call 0207 540 7117
  • Further information, including prescribing information for DuoResp Spiromax®, Aerivio Spiromax® or Qvar® Easi-Breathe® is available from the DuoResp Spiromax® page, the Aerivio Spiromax® page and the Qvar® page
  • You can also request a visit from a Territory Manager here

Joint Working

Joint Working

We work in partnership with multiple Clinical Commissioning Groups across the country to deliver improved patient outcomes. This is through such Joint Working projects as advanced inhaler training, improving patient education and clinical management of asthma and COPD as well as many more projects. Our Joint Working projects are available on our Joint Working pages.

To discuss potential Joint Working opportunities with Teva within respiratory you can contact us and a representative from Teva will be in touch.

1 http://www.asthma.org.uk/asthma-facts-and-statistics accessed 15.03.16

2 http://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease/Pages/Introduction.aspx accessed 15.03.16

3 DuoResp Spiromax® 320 micrograms/9 micrograms and 160 micrograms/4.5
micrograms inhalation powder - Summary of Product Characteristics

4 Price D et al. Resp Med, 2013; 107: 37–46.

5 Qvar® (CFC free beclometasone dipropionate) - Summary of Product Characteristics

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a